Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
64,521,093
-
Total 13F shares
-
28,942,741
-
Share change
-
-1,895,321
-
Total reported value
-
$30,390,733
-
Price per share
-
$1.05
-
Number of holders
-
35
-
Value change
-
-$8,198,090
-
Number of buys
-
16
-
Number of sells
-
17
Institutional Holders of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) as of Q4 2022
As of 31 Dec 2022,
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) was held by
35 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,942,741 shares.
The largest 10 holders included
Sofinnova Investments, Inc., Deep Track Capital, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., Rock Springs Capital Management LP, VR Adviser, LLC, Pivotal bioVenture Partners Investment Advisor LLC, NEA Management Company, LLC, CHI Advisors LLC, SPHERA FUNDS MANAGEMENT LTD., and VANGUARD GROUP INC.
This page lists
35
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.